Edwards Lifesciences' transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In December, Edwards Lifesciences persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis, causing the agency to reconsider its previous stance on covering transcatheter ...

WASHINGTON, D.C.—A randomized trial of patients with a narrowing of their heart’s aortic valve, but who had not yet begun to show the symptoms of cardiovascular disease, demonstrated that replacing ...

Hospital heart team capacity constraints continued to limit Edwards Lifesciences' transcatheter aortic valve replacement (TAVR) sales in the third quarter of 2024, company executives said Thursday on ...

SAN FRANCISCO — After 7 years, transcatheter aortic valve replacement (TAVR) remains equivalent to surgery with respect to durability and safety in low-risk patients, a finding that may blunt ...